# EDGAR Filing Document

**Accession Number:** 0001873093
**File Stem:** 0001641172-25-017783
**Filing Date:** 2025-7
**Character Count:** 3239
**Document Hash:** c387f5da4a467ff64bdf13aa4e0cd9b1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-017783.hdr.sgml**: 20250703

**ACCESSION NUMBER**: 0001641172-25-017783

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250703

**FILED AS OF DATE**: 20250703

**DATE AS OF CHANGE**: 20250703

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CytoMed Therapeutics Ltd
- **CENTRAL INDEX KEY:** 0001873093
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** U0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41677
- **FILM NUMBER:** 251105482

**BUSINESS ADDRESS:**
- **STREET 1:** #08-22 ONE COMMONWEALTH
- **CITY:** 1 COMMONWEALTH LANE
- **STATE:** U0
- **ZIP:** 149544
- **BUSINESS PHONE:** 603824911

**MAIL ADDRESS:**
- **STREET 1:** #08-22 ONE COMMONWEALTH
- **CITY:** 1 COMMONWEALTH LANE
- **STATE:** U0
- **ZIP:** 149544

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CytoMed Therapeutics Pte. Ltd.
- **DATE OF NAME CHANGE:** 20210716

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of July 2025**

**Commission File Number: 001-41677**

**CytoMed THerapeutics Limited**

(Translation of registrant's name into English)

**1 Commonwealth Lane**

**#08-22**

**Singapore 149544**

<br> (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

On May 1, 2025, the Compensation Committee and the Board of Directors of CytoMed Therapeutics Limited (the "Company") approved the issuance of ordinary shares to the following individuals as compensation for their continued service to the Company:

(i) 11,250
 ordinary shares to Dr. Lucas Luk Tien Wee, Chief Clinical Officer, subject to a six-month
 restriction period from the date of issuance;

(ii) 25,781
 ordinary shares to Ms. Goh Yvonne, Chief Financial Officer, subject to a six-month restriction
 period from the date of issuance;

(iii) 25,781
 ordinary shares to Ms. Tan Yoong Ying, Chief Corporate Officer, subject to a six-month restriction
 period from the date of issuance; and

(iv) 469
 ordinary shares to Dr. Yew Chak Hua, Independent Director, subject to a six-month restriction
 period from the date of issuance.

On July 1, 2025, the Company entered into supplemental agreements to the existing appointment agreements with each of the above individuals to formally effect the grant of the respective ordinary shares.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CytoMed Therapeutics Limited.** | **CytoMed Therapeutics Limited.** |
| Date: July 3, 2025 | By: | */s/ Choo Chee Kong* |
|  | Name: | Choo Chee Kong |
|  | Title: | Chairman & Director |

---